This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pasterkamp, G. Articles by Cherr, G. S. Search for Related Content PubMed PubMed Citation Articles by Pasterkamp, G. Articles by Cherr, G. S. Related Collections Lipids Pathophysiology Risk Factors Oxidant stress Mechanism of atherosclerosis/growth factors

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1241.)
© 2002 American Heart Association, Inc.

Letters to the Editor

MMP Inhibition and Lumen Loss After Balloon Angioplasty or Stenting

Gerard Pasterkamp; Marion J. Sierevogel; Dominique P.V. de Kleijn

Department of Cardiology Utrecht Medical Center Utrecht, the Netherlands

Bradley H. Strauss

Department of Cardiology St. Michaels Hospital Toronto, Canada

An extract of the first 250 words of the full text is provided, because this article has no abstract.

To the Editor:

With interest we read the paper by Cherr et al¹ reporting the negligible effect of matrix metalloproteinase (MMP) inhibition on constrictive remodeling and intimal hyperplasia after balloon angioplasty and stenting, respectively. As the authors mentioned, the results are at odds with observations from several published studies that have reported a significant reduction of late lumen loss after intervention by MMP inhibition.^2-4 Several possible explanations were proposed to account for these differences, including route of administration and lack of activity of the compound used by Cherr et al¹ against tumor necrosis factor-–converting enzyme and MMP-1. However, other explanations for these controversial results may be considered.

First, we agree with the authors that the spectrum of MMP inhibitory activity, and thus clinical effects, may significantly differ among compounds. Marimastat and GM6001 are two nonspecific MMP inhibitors with potent inhibitory MMP-1 activity that have been shown to inhibit constrictive remodeling after balloon angioplasty and in-stent intimal hyperplasia, respectively. This result may point to an important role for the breakdown of intact collagen fibers in subsequent response to injury. However, we feel that the route of administration cannot adequately explain the observed differences among studies. Significant inhibition of constrictive remodeling after balloon injury was achieved by both oral³ and parenteral² preparations whereas subcutaneous delivery of GM6001 significantly inhibited in-stent intimal hyerplasia.⁴

Second, we feel that differences in animal models may also explain the lack of inhibitory effect on post-angioplasty constrictive remodeling in the study by Cherr et al.¹ In an earlier publication, Geary . . . [Full Text of this Article]

Randolph L. Geary; Gregory S. Cherr

Departments of Surgery and Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC